Valor202020212022202320242025TTMGastos comerciales, generales y administrativos119.62 M183.87 M215.83 M218.11 M263.37 M290.51 M290.51 MInvestigación y desarrollo20.18 M34.27 M43.94 M42.72 M43.2 M54.18 M54.18 MBeneficio operativo69.82 M167.25 M224.67 M54.58 M-35.11 M55.17 M55.17 MTotal de ingresos no operativos-10.61 M-13.71 M-5.53 M9.56 M8.08 M7.22 M7.22 MGastos por intereses, netos de intereses capitalizados12.13 M12.71 M1.16 M1.95 M20.73 M21.51 M21.51 MIngresos no operativos, una vez deducidos los gastos por intereses-22.52 M-25.27 M2.84 M-518 K-7.48 M-17.11 M-17.11 MIngresos/gastos extraordinarios-214 K-1.16 M-9.53 M8.12 M-5.17 M2.81 M2.81 MBeneficio antes de impuestos59.22 M153.54 M219.14 M64.13 M-27.04 M62.38 M62.38 MParticipación en los beneficios———————Impuestos-709 K25.25 M33.18 M22.55 M-1.52 M13.49 M13.49 MParticipación minoritaria———————Otros ingresos/gastos después de impuestos-267 K-851 K100 K-1.23 M230 K-1.63 M-1.63 MBeneficio neto antes de actividades interrumpidas59.93 M128.29 M185.96 M41.58 M-25.51 M48.89 M48.89 MOperaciones suspendidas———————Beneficio neto59.93 M128.29 M185.96 M41.58 M-25.51 M48.89 M48.89 MAjuste por dilución———————Dividendos de las acciones preferentes———————Beneficio neto diluido atribuible a los accionistas59.93 M128.29 M186.35 M41.58 M-25.51 M48.89 M48.89 MBeneficio básico por acción1.142.333.350.75-0.460.870.87Beneficio por acción diluido1.112.243.240.74-0.460.860.86Número medio de acciones ordinarias52.55 M55.02 M55.46 K55.72 K55.94 K56.23 K224.86 KAcciones diluidas53.89 M57.26 M57.45 K56.38 K55.94 K56.56 K226.16 KEBITDA107.79 M217.28 M277.49 M125.12 M50.17 M150.61 M132.56 MEBIT69.82 M167.25 M224.67 M54.58 M-35.11 M55.17 M55.17 MCosto de los ingresos156.63 M279.28 M345.83 M353.92 M359.79 M352.01 M352.01 MOtros costes de producción———————Amortización y depreciación (flujo de caja)37.97 M50.03 M52.81 M70.55 M85.29 M95.45 M77.39 M
Repligen Corporation
Repligen Corporation is a global life sciences company devoted to the development and commercialization of innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. The company is based in Waltham, Massachusetts, and was incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. As of 2025, Repligen employs over 1,900 employees globally and serves primarily biopharmaceutical drug developers and contract development and manufacturing organizations worldwide.